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ABSTRACT  26 
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Therapies to reduce liver fibrosis and stimulate organ regeneration are urgently needed. We 27 
conducted a first-in-human, phase 1 dose-escalation trial of autologous macrophage therapy 28 
in 9 adults with cirrhosis and Model for End-Stage Liver Disease (MELD) score of 10-16 29 
(ISRCTN10368050). Groups of 3 participants received a single peripheral infusion of 107, 108, 30 
or up to 109 cells. Leukapheresis and macrophage infusion was well-tolerated with no 31 
transfusion reactions, dose-limiting toxicities or macrophage activation syndrome. All 32 
participants were alive and transplant-free at 1 year, with only 1 clinical event recorded, the 33 
occurrence of minimal ascites. The primary outcomes of safety and feasibility were met. This 34 




Globally, liver cirrhosis currently causes 1.16 million deaths every year. In the US, among 39 
people aged 45–64 years, chronic liver disease is the 4th leading cause of death.1 Cause-40 
specific interventions are effective, but patients often present with advanced liver disease and 41 
cirrhosis. No curative options are available for cirrhosis except for organ transplantation which 42 
requires major surgery and lifelong immunosuppression. Donor organ availability also restricts 43 
access to transplantation.2 Alternative therapies to treat cirrhosis are therefore being 44 
developed including cell therapies.3,4 45 
The macrophage is a cellular regulator of liver fibrosis deposition and resolution.5 During 46 
disease progression macrophages release signals which drive inflammatory cell recruitment 47 
and activation of hepatic stellate cells to produce extracellular matrix (ECM). Following 48 
cessation of injury, macrophages release matrix metalloproteinases (MMPs) that promote 49 
fibrotic ECM degradation, and factors that dampen the inflammatory response6-8,9 and drive 50 
liver regeneration.7,10   51 
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In mouse models of liver fibrosis, macrophages injected via a peripheral vein home to the liver, 52 
express MMPs, and recruit host immune cells to liver scar via chemokine expression, 53 
ameliorating liver fibrosis, stimulating liver regeneration and improving function.10  Circulating 54 
CD14+ monocytes can be isolated from cirrhotic patient mononuclear cell (MNC) 55 
leukapheresis products with high yield and purity and can be differentiated using Good 56 
Manufacturing Practice (GMP)-compliant processes into macrophages with a comparable 57 
phenotype to those from healthy volunteers.11,12 These macrophages can also resolve liver 58 
fibrosis in mouse models.12 These data prompted us to conduct a first-in-human, phase 1, 59 
single-arm, dose-escalation clinical trial in people with cirrhosis evaluating maximum-tolerated 60 
dose and safety of peripheral infusion of ex vivo matured autologous monocyte-derived 61 
macrophages.  62 
 63 
RESULTS 64 
Trial population, baseline and treatment characteristics 65 
11 participants (4 female and 7 male, mean age 58.54±5.85) with compensated liver cirrhosis 66 
and MELD score between 10 and 16 attended a single centre (Royal Infirmary of Edinburgh, 67 
UK) for screening between 08 August 2016 and  27 March 2017 (Fig. 1). Two individuals did 68 
not meet screening criteria. Nine participants were enrolled in the trial and were followed-up 69 
for 1 year to 06 April 2018. Demographic and baseline characteristics of study participants are 70 
shown in Table 1. The mean duration of cirrhosis was 5.22±4.22 years. All participants were 71 
abstinent from alcohol at the time of recruitment except for one individual who had a history of 72 
intermittent low-level alcohol consumption (1-10 units per week). A week before the planned 73 
treatment, participants underwent a standard leukapheresis to collect circulating monocytes. 74 
Monocytes were isolated from MNC and the Investigational Medical Product (IMP) produced 75 
in a GMP-accredited facility (Extended Data 1). 76 
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Each group of 3 participants (9 in total) received a single infusion of autologous macrophages 77 
at 107, 108 or up to 109 cells, respectively in a dose-escalation manner. All participants were 78 
successfully evaluated for safety, feasibility and maximum-achieved safe dose of autologous 79 
macrophages. We also measured changes in: markers of liver fibrosis (serum Enhanced Liver 80 
Fibrosis (ELF™) test (Siemens Healthineers, UK), serum PRO-C3 and C3M (Nordic 81 
Bioscience, Denmark) and transient elastography (Fibroscan®, Echosens, France)); liver 82 
function (MELD and UKELD scores); health-related quality of life (HRQL) using the Chronic 83 
Liver Disease Questionnaire (CLDQ) instrument; transplant-free survival and number of 84 
clinical events related to decompensation of cirrhosis.  85 
Safety outcomes 86 
All participants completed 1-year of follow-up after macrophage infusion. No participants 87 
withdrew from the study and none developed acute transfusion reactions during macrophage 88 
infusion or in the 12h post-infusion observation period. A total of 3 serious adverse events 89 
were recorded; these were assessed as mild in severity, unrelated to the IMP and there were 90 
no sequelae (Table 2). There were 70 adverse events documented in the reporting period 91 
(Table 2). A single clinical event occurred, described as a small volume of ascites around the 92 
liver on ultrasound. 9/22 (41%), 8/19 (42%) and 6/29 (21%) adverse events were considered 93 
possibly related to the IMP in the 107, 108 and up to 109 cell dose groups, respectively. Overall, 94 
56% of adverse events were considered unrelated to the IMP. No dose-toxicity relationships 95 
were identified.  At the end of the study period all 9 participants were alive and transplant-free.  96 
Serum ALT and bilirubin changes at 90-days were respectively 0.88±0.21 and 0.80±0.30-fold 97 
from baseline. Fluctuation in platelet count is common in patients with cirrhosis and portal 98 
hypertension, but we did not observe a reduction in platelets to lower than 30% from baseline 99 
or clinically significant thrombocytopenia. The baseline total white cell count varied in this 100 
study population. As expected, total circulating leukocyte counts were affected by 101 
leukapheresis, but returned to baseline prior to infusion (7 days after leukapheresis). In some 102 
individuals we noted a small and transient increase in white cell count following infusion of 103 
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macrophages which did not persist beyond 7 days post-infusion (Extended Data 2). Serum 104 
cytokines (including IL1, IL6, IL8, IL10, TNF and IFNγ) did not change significantly from 105 
baseline (Extended Data 3). Specifically, levels of IL8 (which correlate with risk of macrophage 106 
activation syndrome (MAS)) decreased transiently after macrophage infusion, with a delta of 107 
-8.23±14.39 pg/mL at 30 days and of -1.58±13.54 pg/mL at 90 days.  108 
 109 
Secondary outcomes 110 
At day 90 following macrophage infusion, six out of 9 participants showed a decrease in MELD 111 
score (Fig. 2 and Extended Data 4). For all patients, the MELD at baseline was 11.88±1.40 112 
(range 9.90 to 13.87) with a mean Δ-MELD at 90 days of -1.12±1.87 (range -4.90 to 1.76). 113 
(Fig. 2 and Extended data 4). At 1-year follow-up MELD decreased in 7 out of 9 participants; 114 
with a mean Δ-MELD for all patients at 1 year of -0.910±1.24 (range -2.41 to 1.68). Overall, 115 
we did not observe a clear dose-related response; however, in the highest cell group the 116 
MELD scores all followed a similar downward trajectory over the period of follow up (Fig. 2). 117 
The mean Δ-UKELD score for all participants at 90 days was -0.42±2.27. Serum albumin 118 
levels at 90 days showed little change from baseline in all participants with mean Δ-albumin 119 
of -0.20±.0.23 g/dL, with range +0.2 to -0.5  (Extended Data 5). Similarly, INR was unaffected 120 
in all participants by macrophage infusion, with mean ±SD change from baseline of -0.04±0.09 121 
and -0.06±0.09 at 90 days and 360 days respectively.  122 
To detect a change in fibrosis, a range of non-invasive markers of liver fibrosis were quantified. 123 
The technical success rate of transient elastography was 91.66%. Data not meeting the quality 124 
specification as per manufacturer recommendation were removed (2 baseline and 1 90-day 125 
measurements). Baseline liver stiffness measurements were consistent with cirrhosis (mean 126 
57.44±24.01 kPa). In 5 out of 9 participants liver stiffness measurements decreased by >6 127 
kPa at 1-year of follow-up, with an overall mean reduction of -11.91±10.55 kPa (Extended 128 
Data 6). While a change of 6 kPa might be considered meaningful in the context of pre-cirrhotic 129 
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liver fibrosis,13  the importance of this change in established cirrhosis is uncertain. There was 130 
a downward trend in ELF scores following macrophage infusion (Fig. 3a). The mean ELF score 131 
at baseline was 12.43±0.94 with mean delta-ELF at 90 days of -0.24±0.46 and at 1 year of -132 
1.13±1.21 (Extended Data 7). There was a similar change in serological markers of type-III 133 
collagen turnover, with mean % change of PRO-C3 of -14.86±14.50 and % change of C3M of 134 
-10.95±13.37 ng/mL at day 90 (Fig. 3b-c). The larger % decrease in PRO-C3 could indicate a 135 
predominant decrease in fibrogenic activity following infusion of macrophages. Longitudinal of 136 
health-related quality of life scores (HRQL) assessment showed relatively small variations in 137 
composite Chronic Liver Disease Questionnaire (CLDQ) scores over time, but 5 out of 9 138 
participants showed an improvement in overall HRQL at day 90 post-macrophage infusion 139 
(Fig. 3d and Extended Data 8). Individual domain scores are shown in Extended Data Table 140 
1.  141 
 142 
DISCUSSION 143 
This first-in-human trial confirmed the safety and feasibility of a single peripheral infusion of 144 
autologous macrophages in participants with compensated liver cirrhosis of differing aetiology. 145 
Leukapheresis was well-tolerated by all participants with minimal side effects. Administration 146 
of macrophages was safe, with no clinically relevant adverse reactions recorded during the 147 
infusion or in the immediate post-infusion period. The 3+3 trial dose-escalation model is 148 
designed to define a maximum-tolerated dose. Due to monocyte isolation and production 149 
limitations, we were able to generate a “maximum-achieved dose” of up to 109 cells 150 
(specifically 0.8 x 109 cells), for which we sought to determine the safety and feasibility.  151 
As expected, in a study population with advanced cirrhosis and other co-morbidities, we 152 
observed adverse events throughout the study. One participant had a previous history of 153 
intermittent low-level alcohol consumption, but serial gamma-glutamyl transpeptidase (GGT) 154 
levels (a biochemical marker of alcohol consumption) remained static at all follow-up visits, 155 
suggesting that this did not influence the measured outcomes for this patient. Most of the 156 
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adverse events recorded in the study were exacerbations of existing conditions or minor self-157 
limiting events. The 3 serious adverse events were considered mild and unrelated to the IMP. 158 
Among AEs possibly related to the IMP, none had Common Terminology Criteria for Adverse 159 
Events (CTCAE) severity grading over 2. There were no dose-related phenomena. All 160 
participants reached 360 days of follow-up and were transplant-free. We listed a single clinical 161 
event (worsening ascites) during the whole follow-up period. This was identified on ultrasound 162 
and resolved with diuretics. All other participants remained well compensated.  163 
Although we did not label the infused macrophages, previous animal models and human case 164 
reports14 suggest that macrophages infused via peripheral or central veins will transiently pass 165 
through the lungs, before engrafting in the liver and spleen.10,15,16 While this does not prove 166 
that the cell product used in our study reached the liver, these observations are supportive. 167 
We did not record any clinically meaningful changes in respiratory rate or oxygen saturation 168 
at any point during infusion or 12-hour follow-up period. Overall the IMP appeared safe during 169 
administration and the extended follow-up period of 360 days. 170 
This single-arm phase 1 study was not designed or powered to demonstrate statistically 171 
significant changes in efficacy measures following macrophage therapy. However, in 6 of 9 172 
participants reductions in MELD score were observed at 90 days, largely due to a decrease 173 
in serum bilirubin. This contrasts with a recent RCT using autologous CD133+ stem cells in 174 
adults with cirrhosis of comparable severity to this study which showed no improvement in 175 
MELD score.17  In one individual, total bilirubin and MELD score were higher at 360 days of 176 
follow-up compared to baseline; however, over 85% of the total bilirubin was unconjugated, 177 
representing haemolysis likely due to cold agglutinins (the patient had treated hepatitis C with 178 
sustained viral response). Other parameters of liver function did not change in response to 179 
cell infusion, including UKELD score and serum albumin. Overall, no robust dose-dependent 180 
treatment effects were observed in secondary outcomes.   181 
The macrophages manufactured using GMP-compliant processes have been 182 
comprehensively characterised and demonstrate a mature phenotype (CD14+ / high 25F9 183 
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expression), plus retention of high levels of markers associated with tissue repair and 184 
inflammation resolution (CD206, CD163 and CD169).11 185 
A number of non-invasive measures of liver fibrosis improved following macrophage infusion 186 
including transient elastography, serum ELF score and the collagen turnover markers PRO-187 
C3 and C3M, highlighting the potential antifibrotic effect of autologous monocyte-derived 188 
macrophage infusion in cirrhosis.  189 
There was variability in measured responses to macrophage infusion, even in participants 190 
treated with the same cell dose. This likely reflects the multiple factors that could determine 191 
the effect of macrophage infusion in an individual with cirrhosis such as duration and aetiology 192 
of liver disease, other comorbidities, or engraftment and survival of the infused macrophages 193 
in the liver. The influence of these variables will be better addressed in a larger randomised 194 
controlled phase 2 trial. 195 
Impairment of HRQL is reported by most patients with advanced cirrhosis and HRQL scores 196 
improve significantly following liver transplantation.18 Given that a change of 0.5 on the 1 to 7 197 
scale represents an important difference in CLDQ score, 5 of 9 participants exhibited an 198 
improvement in overall HRQL score at day 90 post-infusion.19 In the remaining participants, 199 
composite CLDQ scores were either unchanged (n=2) or worse (n=2) at 90 days. Interestingly, 200 
there was an improvement in most participants in the emotional domain at day 90 post-201 
infusion. We noted an inverse association between delta-MELD and CLDQ scores. Moreover, 202 
in the 4 individuals in whom MELD failed to decrease or worsened, we observed no 203 
improvement in HRQL. 19 204 
This first-in-human study confirmed the safety, feasibility and maximum-achievable dose of 205 
autologous macrophages and facilitate future efficacy studies in cirrhosis and other fibrotic 206 
diseases. The effects of macrophage therapy upon efficacy measures including transplant-207 
free survival, MELD and UKELD score, fibrosis markers and HRQL will be evaluated in an 208 







107 Cells (n=3) 108 Cells (n=3) Up to 109 Cells (n=3) 
    0.6x109 0.8x109 0.7x109 
Participant ID 001 002 003 004 005 006 007 008 009 010 011 
DEMOGRAPHICS 
Mean Age 63.00 ±5.66 59.33 ±8.50 55.67 ±6.35 57.67± 2.88 
Body Mass Index 32.1 28.2 24.7 29.6 35.6 26 27.8 27.8 33.6 27.6 29 
Sex (Male:Female) 2:0 1:2 3:0 1:2 
Ethnicity All Caucasian All Caucasian All Caucasian All Caucasian 
AETIOLOGY OF LIVER DISEASE 
ALD (n) 1 2 2 2 
NAFLD (n) 1 0 0 1 
HCV (SVR) (n) 0 0 1 0 
PBC (n) 0 1 0 0 
SEVERITY OF CIRRHOSIS 
MELD score   13 11 14 13 10 13 10 13 11 
Mean MELD score   12.37±1.51 11.90±1.48 11.36±1.62 
UKELD score   50 50 50 51 51 51 48 51 47 
Child-Pugh score   6 5 7 6 6 8 5 9 9 
Child-Pugh class   A A B A A B A B B 
LIVER DISEASE COMPLICATIONS 
Ascites x  x    x x  x x 
SBP            
Variceal bleeding   x    x x  x x 
Hepatic 
encephalopathy 
         x x 
 211 
Table 1. Baseline characteristics of trial participants classified by cell dose group. ALD, 212 
alcohol-related liver disease; NAFLD, non-alcoholic fatty liver disease; HCV, hepatitis C virus; 213 
SVR, sustained viral response (> 6 months); PBC, primary biliary cholangitis; MELD, Model 214 
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for End-Stage Liver Disease; UKELD, United Kingdom Model for End-Stage Liver Disease; 215 





















Adverse Event 107 cell dose 108 cell dose 
Up to 109 cell 
dose 
Nausea 1 0 0 
Abdominal pain 0 2 3 
Anorexia 0 1 0 
Light-headedness 1 2 2 
Fatigue 1 1 3 
Chest pain 4 6 0 
Joint pain/malaise 2 2 3 
Rash 2 0 3 
Hypocalcaemia symptoms (leukapheresis) 1 2 3 
Ascites 0 1 0 
Anaemia 1 1 0 
Infective 3 0 2 
Others 5 1 10 
TOTAL 22 19 29 
Number of probably related AEs 9 (41%) 8 (42%) 6 (21%) 
Type of Serious Adverse Event     
Abdominal pain and constipation   2 
Papillary lesion of breast 1   
 235 
Table 2. Recorded adverse events and serious adverse events during the study period. 236 
Adverse events (AEs) and serious adverse events (SAEs) classified by dose, using Medical 237 
Dictionary for Regulatory Activities (MedDRA) coding version 20.0. All AEs listed were defined 238 
as grade 1 or 2 according to the Common Terminology Criteria for Adverse Events version 239 
5.0. All the SAE were considered unrelated to the macrophage infusion. Two, although rated 240 
of mild severity, resulted in overnight admission to hospital. The SAE relative to the incidental 241 
finding of a papillary lesion of breast through screening mammogram led to surgical excision 242 





Fig. 1. Trial profile. A 3+3 model for dose escalation was used. During the study, there was 246 
no dose-limiting toxicity (DLT); therefore, only 9 participants were needed to complete the 247 



















Fig. 2. MELD score over time per cell dose group. Each line represents a participant in 265 
the trial. Time-points indicate the time of macrophage infusion (purple line; approximately 14 266 
days from baseline) and study-specific follow-up visits in the trial. Primary and secondary 267 





Fig. 3. Secondary outcomes a) Individual participant ELF score changes from baseline (BL) over 
time (delta-ELF). b) Individual participant PRO-C3 level changes from baseline over time (% 
changes of PRO-C3). c) Individual participant C3M level changes from baseline over time (% 
changes of C3M). d) Individual self-reported health related quality of life (HRQL) measures over 
time, expressed as the composite Chronic Liver Disease Questionnaire (CLDQ) score and not delta 
changes to highlight the significant variability in baseline HRQL composite score in this population. 
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The MATCH 0.1 trial is an investigator-led study, funded by the Medical Research Council 
(Reference: MR/M007588/1) and sponsored by ACCORD (Academic and Clinical Central Office for 
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Research and Development for NHS Lothian/University of Edinburgh). All study-related documents 
were designed by the trial team with input from ACCORD, an independent statistician and the 
Scottish National Blood Transfusion Service (SNBTS) team. The trial was approved by Scotland A 
Research Ethics Committee (Reference: 15/SS/0121), NHS Lothian Research and Development 
department and the Medicine and Health Care Regulatory Agency (MHRA-UK). The trial was 
registered in the International Standard Randomized Controlled Trial registry (ISRCTN10368050) 
and the European Clinical Trial Database (Reference: 2015-000963-15). All participants enrolled in 
the study gave informed consent and the trial was conducted under Good Clinical Practice 
regulations.  
Study design   
A phase 1 first-in-human trial using a standard 3+3 dose-escalation design was conducted in a single 
centre (Royal Infirmary of Edinburgh, Edinburgh, UK).20 Due to limitations in production and cell 
selection, the maximum number of cells that could be produced for infusion was 109; this study was 
therefore designed to ascertain the tolerability of the maximum-achievable dose and not the 
maximum-tolerated dose. This approach was approved by the appropriate oversight bodies (Phase 
I/First in Human Study Review Committee, Data Monitoring Committee and Trial Steering 
Committee). Escalation decisions were taken by an independent Data Monitoring Committee and 
recommendations discussed within the Trial Steering Committee and acted upon before each dose-
escalation.  
Study participants  
All participants were recruited through the hospital outpatient service in NHS Lothian between 08 
August 2016 and 06 April 2018. 9 adult participants with liver cirrhosis of different aetiologies and a 
MELD score between 10 and 16 were enrolled. To confirm eligibility only, we used a MELD calculator 
adopted by the transplant coordinators within our unit; this rounds MELD score to the nearest integer. 
Full inclusion and exclusion criteria are detailed in the protocol in the Extended Data. Inclusion 
criteria included: age 18-75; MELD score 10-16 (inclusive); liver disease aetiology of alcohol-related 
liver disease, primary biliary cholangitis, non-alcoholic fatty liver disease, cryptogenic cirrhosis, 
haemochromotosis, alpha-1 antitrypsin deficiency or treated chronic hepatitis C (sustained viral 
18 
 
response); liver cirrhosis (diagnosed by at least one of: liver biopsy, Fibroscan™ median liver 
stiffness measurement >15 kPa, or clinical and radiological evidence consistent with cirrhosis). 
Exclusion criteria included: history of decompensated cirrhosis in the previous 3 months (portal 
hypertensive bleeding, ascites requiring medical treatment or hepatic encephalopathy requiring 
hospitalisation); hepatocellular carcinoma or undetermined liver nodules; cancer in the previous 5 
years (excluding adequately treated and localised skin cancer or carcinoma-in-situ of the cervix); 
previous organ or tissue transplantation; listed for liver transplant; pregnancy and breastfeeding; 
presence of acute illness that may compromise safety of the patient in the trial. No active alcohol 
misuse ≥6 calendar months prior to screening was permitted. Individuals attended for a screening 
visit to ensure eligibility 7±4 days before scheduled leukapheresis. Participants underwent 
leukapheresis a week before infusions. The Investigational Medical Product (IMP) was produced in 
a GMP-accredited facility. On the day of infusion, active infection was excluded by physical 
examination and laboratory investigations. Prior to infusion, 10 mg i.v. chlorphenamine and 100 mg 
i.v. hydrocortisone was administered. Each group of 3 participants received a single infusion given 
over 30 +/- 5 minutes of 107, 108 and up to 109 cells, respectively.  
Study Assessments 
During infusion, participants were monitored closely and observed overnight in the RIE Clinical 
Research Facility (CRF). Special arrangements were in place with the intensive care unit in the event 
of a severe reaction. The following morning full blood count, renal function, electrolytes, liver function 
tests, triglycerides and ferritin were checked prior to discharge to exclude toxicity, including 
Macrophage Activation Syndrome (MAS). 
During the first two follow-up visits (day 7 and day 14 after IMP infusion) safety, dose-limiting toxicity 
(DLT) and the presence of MAS were assessed. The definition of DLT was formulated using 
accepted criteria21-24. serum creatinine ≥ 1.5-fold from baseline, haemoglobin 1.5-fold ≤ baseline, 
platelets < 2-fold from baseline, total white cell count < 2.0 x 109, alanine aminotransferase (ALT) > 
3-fold from baseline, total bilirubin > 3-fold from baseline, MELD score > 4 points from baseline. 
Thereafter, participants were followed up at day 30, 60, 90, 180 and 360 after IMP infusion with 
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routine and biomarker blood tests, abdominal ultrasound, transient elastography and health-related 
quality of life (HRQL) assessment (full details are provided in the Protocol in the Extended Data).   
Transient elastography (Fibroscan®, Echosens, France) is a well-validated non-invasive test to 
quantify liver fibrosis. It records the velocity of a sound wave passing through the liver and then 
converts that measurement into a liver stiffness value (expressed in kilopascals (kPa)).13  
A range of serological biomarker tests are available for assessment of liver fibrosis. We used the 
Enhanced Liver Fibrosis (ELF™ test (Siemens Healthineers, UK)), a biochemical panel comprising 
serum markers that are indicators of ECM metabolism (hyaluronic acid, procollagen-III N-terminal 
pro-peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1)). The composite 
ELF score has been validated for detection of liver fibrosis and for prognostication in chronic liver 
disease.25,26 By serological assessment of specific ECM fragments it may be possible to separate 
tissue formation from tissue degradation.27 We also measured PRO-C3 and C3M (Nordic Bioscience 
Protein Fingerprint™ technology) which are two markers derived from type-III collagen remodeling, 
i.e. N-terminal pro-peptide and MMP-9 degraded collagen fragment from the helix region, 
respectively,28,29 with utility for staging liver fibrosis and monitoring response to antifibrotic 
therapy30,31.  
Liver function was assessed by the MELD and the United Kingdom Model for End-Stage Liver 
Disease (UKELD). These are established clinical scores calculated from objective variables (serum 
bilirubin, creatinine, International Normalized Ratio (INR) and sodium) that are used to estimate the 
severity of liver disease, determine prognosis and prioritize patients for transplantation.32,33  
The Chronic Liver Disease Questionnaire (CLDQ) is a 29-item self-reported disease-specific 
instrument, measuring HRQL in the following domains: fatigue, activity, emotional function, 
abdominal symptoms, systemic symptoms, and worry. A composite score is calculated by the 
patient’s response options in each domain using seven-point scales, ranging from the worst (1) to 
the best (7) possible function. The CLDQ is reliable, responsive and correlates with the severity of 
liver disease.19,34  
Serum cytokines were analysed using a V-PLEX Human Biomarker 54-Plex kit on a MESO 
Quickplex SQ 120 according to the manufacturers’ instructions (Meso Scale Discovery). We selected 
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a set of 6 safety-related cytokines associated with ‘cytokine storm’ in MAS. These were IL8 (pivotal 
in the pathogenesis of MAS), IL1, IL6, TNF, IFNγ and IL10. 
Method of cell production 
The monocyte-derived macrophages were manufactured as previously described.11 Briefly, steady-
state leukapheresis was collected from each patient (standard MNC program, 2.5 blood volume). 
Monocytes were isolated using a CliniMACS Prodigy® cell processor, programme LP14, tubing set 
TS510 with CliniMACS CD14 Reagent (all Miltenyi). Up to 3.5x1010 TNC containing 4x109 CD14+ 
cells were processed in a single operation. Mean CD14+ cell purity was 98.3%±0.7% and the mean 
selection yield of 55.25%±5.4%. A total of 2x109 CD14+ cells were cultured in 4x gas-permeable 
plastic bags (MACS GMP cell differentiation bag 500, Miltenyi Biotec) at 1x106 cells per ml in 
TexMACS GMP (phenol red-free) medium supplemented with 100 ng/mL M-CSF (GMP-grade, RND 
systems). Medium was replenished by removing 50% spent medium and replacing with 50% fresh 
medium supplemented with 200ng/mL M-CSF after 48 and 96 hours of culture. After 7 days, 
macrophages were harvested, counted and formulated into saline for injection supplemented to 0.5% 
Alburex (CSL Behring UK). Macrophages were characterized as viable, CD45+, CD14+, 25F9+ cells 
as previously described.11 CD14+ monocytes were successfully isolated from all participants. A 
macrophage product was successfully manufactured and administered for all participants. 
Statistics 
A descriptive analysis of the primary outcome of safety and tolerability is presented. Secondary 
outcomes are presented graphically by dose and as changes from baseline. Unless stated, 
numerical data is expressed as mean±standard deviation (SD). A safety report was produced to 
review the day 14 results of the first participant, thereafter DMC reports were produced following the 
day 14 safety blood samples of each escalation group of 3 participants at each dose level or as 
required by serious adverse events. Any additional analysis was performed at the end of the trial 
once the electronic database was locked following quality checks (QC). There was 100% QC of the 
data collected, with no missing data other than a single collagen biomarker sample at day 60 post-




Data in the published article (and its Supplementary Information files) has been presented where 
possible in aggregated form.  Any data presented to illustrate individual patient performance has 
been de-identified and only includes analysis of performance within the trial (such as MELD 
score). The datasets generated during and/or analysed during the current study are available from 
the corresponding author (SJF) upon reasonable request, although restrictions may apply due 
to patient privacy and General Data Protection Regulation. 
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